Sorrento Therapeutics (0L85) Financial Statements
Sorrento Therapeutics Financial Overview
Sorrento Therapeutics's market cap is currently $165.38K. The company's EPS TTM is $-1.14; its P/E ratio is 0.00; Sorrento Therapeutics has not announced its next earnings date. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 22 | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 62.84M | $ 52.90M | $ 39.99M | $ 31.43M | $ 21.19M |
| Gross Profit | $ 29.39M | $ 39.87M | $ 30.05M | $ 19.20M | $ 11.12M |
| Operating Income | $ -504.31M | $ -368.05M | $ -201.53M | $ -195.18M | $ -129.48M |
| EBITDA | $ -539.93M | $ -439.84M | $ -279.42M | $ -313.54M | $ -147.10M |
| Net Income | $ -572.84M | $ -429.01M | $ -298.46M | $ -359.10M | $ -203.54M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 49.98M | $ 126.88M | $ 56.46M | $ 22.52M | $ 168.63M |
| Total Assets | $ 472.84M | $ 694.82M | $ 535.82M | $ 557.63M | $ 674.73M |
| Total Debt | $ 134.50M | $ 237.58M | $ 169.39M | $ 294.10M | $ 233.29M |
| Net Debt | $ 110.87M | $ 200.91M | $ 112.93M | $ 271.58M | $ 64.96M |
| Total Liabilities | $ 494.51M | $ 616.69M | $ 395.09M | $ 524.88M | $ 467.23M |
| Stockholders' Equity | $ -18.61M | $ 78.75M | $ 165.15M | $ 78.59M | $ 209.47M |
| Cash Flow | |||||
| Free Cash Flow | $ -307.51M | $ -290.69M | $ -197.12M | $ -184.44M | $ -132.96M |
| Operating Cash Flow | $ -293.86M | $ -281.82M | $ -159.54M | $ -173.00M | $ -111.77M |
| Investing Cash Flow | $ -28.52M | $ 79.85M | $ -39.92M | $ -38.17M | $ -21.20M |
| Financing Cash Flow | $ 311.72M | $ 181.33M | $ 174.24M | $ 78.89M | $ 326.00M |
Currency in USD